Document is current
Any future updates will be listed below
-
Authors
Huang, Jiansong
Zhou, Jing https://orcid.org/0000-0001-6601-4446
Liu, Xiao
Liu, Xiaoxu
Xiao, Ye
Li, Kai https://orcid.org/0009-0005-8796-8798
Ding, Chenbo https://orcid.org/0000-0002-3236-842X
Cai, Xuemin
Mao, Wenli
Xu, Changfen
Kong, Yuxin
Deng, Yu
Song, Xiaohan https://orcid.org/0009-0004-6176-7587
Yang, Mei
Du, Daohai https://orcid.org/0000-0002-6623-7778
Guo, Siqi
Chen, Kaixian
Luo, Cheng https://orcid.org/0000-0003-3864-8382
Yi, Chengqi https://orcid.org/0000-0003-2540-9729
Chen, Shijie https://orcid.org/0000-0001-9724-7453
Li, Hua-Bing https://orcid.org/0000-0003-3573-6803
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 26 June 2026
First Online: 22 July 2026
Ethics
Competing interests: The authors declare that H-B.L., J.H., J.Z., C.L., S.C. and X.L. are the inventors on a patent application “Application of Suramin, Its Derivatives, and Pharmaceutical Compositions”, which is relevant to the research about “PCIF1 is a potential therapeutic target for inhibiting tumor growth” presented in this paper. The patent application has been disclosed to the journal, and the authors have provided an approved plan to manage any potential conflicts of interest arising from this arrangement. Other authors declare no competing interests.
